PALB2 and neoplasm: Results showed that adoptive transfer of PBMCs stimulated with PALB2 and ROBO3 leads to reduced tumor growth, while CMV-stimulated PBMCs had no effect, displaying the viability of using neoantigens like PALB2 to induce antitumor immunity [66].